Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 9
2004 10
2005 11
2006 8
2007 9
2008 11
2009 4
2010 3
2011 3
2013 1
2014 1
2015 3
2016 3
2017 1
2018 1
2019 2
2020 9
2021 3
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
The expanding role for small molecules in immuno-oncology.
Offringa R, Kötzner L, Huck B, Urbahns K. Offringa R, et al. Nat Rev Drug Discov. 2022 Nov;21(11):821-840. doi: 10.1038/s41573-022-00538-9. Epub 2022 Aug 18. Nat Rev Drug Discov. 2022. PMID: 35982333 Review.
Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic cancer.
Meng Z, Rodriguez Ehrenfried A, Tan CL, Steffens LK, Kehm H, Zens S, Lauenstein C, Paul A, Schwab M, Förster JD, Salek M, Riemer AB, Wu H, Eckert C, Leonhardt CS, Strobel O, Volkmar M, Poschke I, Offringa R. Meng Z, et al. Among authors: offringa r. Sci Transl Med. 2023 Nov 15;15(722):eadh9562. doi: 10.1126/scitranslmed.adh9562. Epub 2023 Nov 15. Sci Transl Med. 2023. PMID: 37967201
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Kober C, Roewe J, Schmees N, Roese L, Roehn U, Bader B, Stoeckigt D, Prinz F, Gorjánácz M, Roider HG, Olesch C, Leder G, Irlbacher H, Lesche R, Lefranc J, Oezcan-Wahlbrink M, Batra AS, Elmadany N, Carretero R, Sahm K, Oezen I, Cichon F, Baumann D, Sadik A, Opitz CA, Weinmann H, Hartung IV, Kreft B, Offringa R, Platten M, Gutcher I. Kober C, et al. Among authors: offringa r. J Immunother Cancer. 2023 Nov;11(11):e007495. doi: 10.1136/jitc-2023-007495. J Immunother Cancer. 2023. PMID: 37963637 Free PMC article.
Cancer immunotherapy: exploiting neoepitopes.
Platten M, Offringa R. Platten M, et al. Among authors: offringa r. Cell Res. 2015 Aug;25(8):887-8. doi: 10.1038/cr.2015.66. Epub 2015 Jun 2. Cell Res. 2015. PMID: 26032267 Free PMC article.
T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.
Pinkert J, Boehm HH, Trautwein M, Doecke WD, Wessel F, Ge Y, Gutierrez EM, Carretero R, Freiberg C, Gritzan U, Luetke-Eversloh M, Golfier S, Von Ahsen O, Volpin V, Sorrentino A, Rathinasamy A, Xydia M, Lohmayer R, Sax J, Nur-Menevse A, Hussein A, Stamova S, Beckmann G, Glueck JM, Schoenfeld D, Weiske J, Zopf D, Offringa R, Kreft B, Beckhove P, Willuda J. Pinkert J, et al. Among authors: offringa r. Oncoimmunology. 2021 Dec 30;11(1):2008110. doi: 10.1080/2162402X.2021.2008110. eCollection 2022. Oncoimmunology. 2021. PMID: 35141051 Free PMC article.
Anti-p53-directed immunotherapy of malignant disease.
Theobald M, Offringa R. Theobald M, et al. Among authors: offringa r. Expert Rev Mol Med. 2003 Mar 28;5(11):1-13. doi: 10.1017/S1462399403006173. Expert Rev Mol Med. 2003. PMID: 14987396 Review.
108 results